Skip to main content
MedNextMedNext
Drug ComparisonSelective serotonin reuptake inhibitor

Sertraline vs Fluoxetine

Clinical Comparison

Clinical Context

Both are first-line SSRIs, but sertraline is the most commonly recommended first-choice by NICE for depression and anxiety in adults due to its favourable interaction profile. Fluoxetine is preferred in children/adolescents and where discontinuation syndrome is a concern, thanks to its exceptionally long half-life.

Drug Profiles

Sertraline

Selective serotonin reuptake inhibitor (SSRI)

Mechanism

Selectively inhibits serotonin (5-HT) reuptake at the presynaptic terminal, increasing serotonergic neurotransmission

Indications

  • Major depressive disorder
  • Generalised anxiety disorder
  • Panic disorder
  • OCD
  • PTSD
  • Social anxiety disorder

Common Doses

50 mg OD initially, increased in 50 mg increments to max 200 mg OD

Route

Oral

Onset & Duration

Onset of therapeutic effect 2-4 weeks; half-life 26 hours

Fluoxetine

Selective serotonin reuptake inhibitor (SSRI)

Mechanism

Selectively inhibits serotonin reuptake at the presynaptic terminal, with active metabolite (norfluoxetine) extending activity

Indications

  • Major depressive disorder
  • OCD
  • Bulimia nervosa
  • Depression in children and adolescents (age 8+)

Common Doses

20 mg OD, increased to max 60 mg OD (80 mg for OCD/bulimia)

Route

Oral

Onset & Duration

Onset 2-4 weeks; half-life 4-6 days (norfluoxetine: 4-16 days)

Key Differences

Drug interactions

Sertraline

Fewer CYP interactions — generally safer with polypharmacy

Fluoxetine

Potent CYP2D6 inhibitor — avoid with tamoxifen, codeine

Half-life

Sertraline

26 hours — needs tapering to avoid discontinuation

Fluoxetine

4-16 days (with metabolite) — self-tapering, minimal withdrawal

Children/adolescents

Sertraline

Not first-line in under 18s

Fluoxetine

Only SSRI licensed for depression in children (age 8+)

Bulimia nervosa

Sertraline

Not licensed for bulimia

Fluoxetine

Licensed at 60 mg for bulimia nervosa

Cardiac safety

Sertraline

Proven safe post-MI (SADHART trial)

Fluoxetine

Less cardiac safety data

Activation profile

Sertraline

More neutral / mildly sedating

Fluoxetine

More activating — can worsen anxiety initially

Key Advantages

Sertraline

  • Fewer CYP450 drug interactions than fluoxetine
  • NICE first-line SSRI for depression and GAD
  • Safe in cardiac patients (SADHART trial)
  • Well-tolerated with gradual titration

Fluoxetine

  • Very long half-life — minimal discontinuation symptoms
  • Only SSRI licensed for depression in children (age 8+)
  • Licensed for bulimia nervosa
  • Activating profile — may suit patients with lethargy/hypersomnia

Key Cautions

Sertraline

  • GI side effects (nausea, diarrhoea) especially initially
  • Sexual dysfunction
  • Discontinuation syndrome if stopped abruptly
  • Hyponatraemia risk in elderly
  • Serotonin syndrome risk with MAOIs/triptans

Fluoxetine

  • Potent CYP2D6 inhibitor — many drug interactions (tamoxifen, codeine, tramadol)
  • Long half-life means interactions persist for weeks after stopping
  • More activating — may worsen anxiety/insomnia initially
  • Weight loss more common than other SSRIs

Clinical Verdict

Sertraline is the general first-choice SSRI for adult depression and anxiety (fewer drug interactions, cardiac safety). Fluoxetine is preferred in children, bulimia, or when poor medication adherence makes the long half-life advantageous.

Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).

Full monographs for Sertraline & Fluoxetine in the MedNext app

Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.

Download MedNext Formulary